PharmaEngine, Inc.
4162
Rank in Stocks
#16024
PharmaEngine, Inc. is a biopharmaceutical firm specializing in the creation and... PharmaEngine, Inc. is a biopharmaceutical firm specializing in the creation and advancement of oncology therapeutics, primarily targeting markets in Taiwan and Europe. Its leading drug candidate is ONIVYDE, an innovative liposomal formulation of irinotecan. This topoisomerase 1 inhibitor is designed to treat metastatic pancreatic cancer. The company's pipeline also includes PEP06, currently in Phase I clinical trials for various cancers, and PEP07. PEP07, a Chk1 inhibitor in preclinical development, is being investigated for its ability to induce DNA damage and programmed cell death (apoptosis), leading to "replication catastrophe" in cancer cells. Established in 2002, PharmaEngine, Inc. maintains its corporate headquarters in Taipei, Taiwan.
Share Price
$1.61
Last synced: 2026-11-10
Market Cap
$231.70M
Change (1 day)
1.34%
Change (1 year)
-27.03%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade PharmaEngine, Inc. (4162)
Category
Healthcare
EPS for PharmaEngine, Inc. (4162)
EPS as of June 2026 TTM: $0.12
According to PharmaEngine, Inc.'s latest financial reports, its current EPS (TTM) is $0.12. At the end of 2025 the company had an EPS of $0.09, a decrease compared to its 2024 EPS of $0.37.
EPS history for PharmaEngine, Inc. from 2008 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.12 | 28.67% |
| 2025 | $0.09 | -76.79% |
| 2024 | $0.37 | 495.66% |
| 2023 | $0.06 | -14.09% |
| 2022 | $0.07 | -31.95% |
| 2021 | $0.11 | -27.96% |
| 2020 | $0.15 | 1,422.68% |
| 2019 | $0.01 | -66.32% |
| 2018 | $0.03 | -67.53% |
| 2017 | $0.09 | -38.91% |
| 2016 | $0.15 | 77.72% |
| 2015 | $0.08 | 204.85% |
| 2014 | $0.03 | -190.85% |
| 2013 | $-0.03 | -313.77% |
| 2012 | $0.01 | -84.68% |
| 2011 | $0.09 | -569.27% |
| 2010 | $-0.02 | -59.83% |
| 2009 | $-0.05 | 49.38% |
| 2008 | $-0.03 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 13,423.32% |
US
|
|
| $-7.07 | -6,205.35% |
US
|
|
| $-5.29 | -4,668.22% |
AU
|
|
| $12.88 | 11,022.71% |
BE
|
|
| $21.56 | 18,518.31% |
NL
|
Questions about PharmaEngine, Inc.'s earnings per share (EPS)
What is PharmaEngine, Inc.'s earnings per share (EPS)?
PharmaEngine, Inc.'s earnings per share (EPS) over the last twelve months is $0.12, as of Jun 2026.
What was PharmaEngine, Inc.'s earnings per share (EPS) in 2025?
In 2025, PharmaEngine, Inc.'s earnings per share (EPS) was $0.09, 75.68% less than in 2024 ($0.37).
How has PharmaEngine, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, PharmaEngine, Inc.'s earnings per share (EPS) went from $0.15 to $0.09, an average decline of 9.71% a year.
How does PharmaEngine, Inc.'s earnings per share (EPS) compare with similar companies?
PharmaEngine, Inc.'s earnings per share (EPS) ($0.12) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.